fda glp-1 warning letters october 2025 The sent a letter to the maker of Ozempic and Wegovy over unreported potential side effects. Here's what to know FDA warning letters target marketers
Description
[Click to Enlarge] As you can see above, the rate of growth has slowed in the past few years, due partly to the substantial number of products that have already been dropped
Key Players 1
The frequency and severity of gastrointestinal effects represent a significant clinical consideration
The useful question is no longer only how many scripts were supplied? It is: Which patients can access treatment, through which pathway, for which indication, at what cost, with what persistence, and with what outcome
New England Journal of Medicine, 387 (3), 205216
